The stock has a 36-month beta value of 2.69. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRAX is 17.21M, and at present, short sellers hold a 15.51% of that float. On February 28, 2025, the average trading volume of PRAX was 363.42K shares.
PRAX) stock’s latest price update
Praxis Precision Medicines Inc (NASDAQ: PRAX)’s stock price has plunge by -36.85relation to previous closing price of 65.03. Nevertheless, the company has seen a -44.87% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-02-28 that Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.94 per share versus the Zacks Consensus Estimate of a loss of $2.96. This compares to loss of $2.97 per share a year ago.
PRAX’s Market Performance
Praxis Precision Medicines Inc (PRAX) has seen a -44.87% fall in stock performance for the week, with a -44.52% decline in the past month and a -45.01% plunge in the past quarter. The volatility ratio for the week is 7.53%, and the volatility levels for the past 30 days are at 7.27% for PRAX. The simple moving average for the past 20 days is -47.24% for PRAX’s stock, with a -34.07% simple moving average for the past 200 days.
Analysts’ Opinion of PRAX
Many brokerage firms have already submitted their reports for PRAX stocks, with Deutsche Bank repeating the rating for PRAX by listing it as a “Buy.” The predicted price for PRAX in the upcoming period, according to Deutsche Bank is $111 based on the research report published on February 11, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see PRAX reach a price target of $134. The rating they have provided for PRAX stocks is “Outperform” according to the report published on August 05th, 2024.
Needham gave a rating of “Buy” to PRAX, setting the target price at $145 in the report published on June 24th of the previous year.
PRAX Trading at -45.82% from the 50-Day Moving Average
After a stumble in the market that brought PRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.28% of loss for the given period.
Volatility was left at 7.27%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares sank -48.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.43% lower at present.
During the last 5 trading sessions, PRAX fell by -47.64%, which changed the moving average for the period of 200-days by -20.05% in comparison to the 20-day moving average, which settled at $77.73. In addition, Praxis Precision Medicines Inc saw -46.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRAX starting from Nemiroff Alex, who sale 8,239 shares at the price of $80.20 back on Nov 14 ’24. After this action, Nemiroff Alex now owns 10,301 shares of Praxis Precision Medicines Inc, valued at $660,827 using the latest closing price.
Mastrocola Lauren, the Principal Accounting Officer of Praxis Precision Medicines Inc, sale 5,188 shares at $81.78 during a trade that took place back on Nov 14 ’24, which means that Mastrocola Lauren is holding 5,613 shares at $424,318 based on the most recent closing price.
Stock Fundamentals for PRAX
Current profitability levels for the company are sitting at:
- -102.19 for the present operating margin
- 0.79 for the gross margin
The net margin for Praxis Precision Medicines Inc stands at -94.09. The total capital return value is set at -0.43. Equity return is now at value -64.34, with -57.75 for asset returns.
Based on Praxis Precision Medicines Inc (PRAX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -59.94. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1547.31.
Currently, EBITDA for the company is -125.94 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 373.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.96.
Conclusion
To sum up, Praxis Precision Medicines Inc (PRAX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
